drugset / Trial / NCT05312892

Sympathetic Mechanisms in Obesity-Crossover Design

NCT05312892

Phase 1/2 Recruiting 12 enrolled Vanderbilt University Medical Center
RandomizedCrossoverDouble-blindBasic science

Summary

We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.

Timeline

Start
2022-05-20
Primary completion
2028-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified
Subject Moxonidine Small molecule